Targeting ALK in pediatric RMS does not induce antitumor activity in vivo
ConclusionsWhile ALK appears to be a relevant target in RMS in vitro, targeting this kinase in vivo yields no therapeutic efficacy, warranting extreme caution when considering the use of these agents in pediatric RMS patients.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Pediatrics | Rhabdomyosarcoma | Study